|Bid||1.5400 x 800|
|Ask||1.5600 x 1300|
|Day's Range||1.5202 - 1.5900|
|52 Week Range||1.0200 - 1.8200|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2022 - Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Subscribe to Yahoo Finance Plus to view Fair Value for SVRA
Here is how Assertio (ASRT) and Savara Inc. (SVRA) have performed compared to their sector so far this year.
AUSTIN, Texas, June 16, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced molgramostim has been awarded an Innovation Passport for the treatment of aPAP by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). Innovation Passport is the entry point to the ILAP, a novel program aimed at accelerating the time to market and facilitating patient access to medicines in the UK.
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...